University of Hertfordshire

From the same journal

By the same authors

Documents

View graph of relations
Original languageEnglish
JournalRheumatology
Early online date8 Mar 2022
DOIs
Publication statusE-pub ahead of print - 8 Mar 2022

Abstract

Objectives
Control of disease activity in Rheumatoid Arthritis (RA) is a crucial part of its management to prevent long-term joint damage and disability. This study aimed to identify early predictors of poor disease activity at 5 and 10 years, focussing on comorbidities and clinical/sociodemographic factors at first presentation.

Methods
Patients from two UK-based RA cohorts were classified into two groups; low (<3.2) and moderate/high (≥3.2) Disease Activity Score (DAS28) at five/10 years. Clinical variables (e.g., rheumatoid nodules, erosions), sociodemographic factors (e.g., ethnicity, deprivation) and comorbidities were recorded at baseline and yearly thereafter. The Rheumatic Diseases Comorbidity Index (RDCI) quantified patient comorbidity burden. Binary logistic regression models (outcome low versus moderate/high DAS28) were fitted using multiple imputation.

Results
2,701 patients living with RA were recruited (mean age 56.1 years, 66.9% female); five-year data were available for 1,718 (63.4%) patients and 10-year for 820 (30.4%). Baseline RDCI was not associated with DAS28 at five (OR 1.05, 95% CI 0.91 to 1.22) or 10 years (OR 0.99, 95% CI 0.75 to 1.31) in multivariable analyses. Sociodemographic factors (female gender, worse deprivation) and poorer baseline HAQ-DI were associated with DAS28≥3.2 at both timepoints. Being seropositive was associated with five-year DAS28≥3.2.

Conclusion
This study demonstrates an association between sociodemographic and clinical factors and long-term RA disease activity, in models adjusting for comorbidity burden. The findings call for more holistic and targeted patient management in patients with RA and provide insights for more individualised management plans even on first presentation to rheumatology.

Notes

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

ID: 26899013